Javascript must be enabled to continue!
Akt1 is required to maintain lipid droplets for release of HCV infectious virions
View through CrossRef
Abstract
Hepatitis C virus (HCV) relies on the interplay of viral and host factors to complete its life cycle. It has evolved to benefit from Akt activation at some point in the life cycle through a variety of mechanisms. Our preliminary result showed that Akt-specific inhibitor reduced cell culture-derived HCV (HCVcc) infectivity in a dose-dependent manner. To dissect the mechanism, we adopted a two-part cell culture-derived HCV infection protocol with Akt1 small interfering RNAs (siRNAs) to determine the role of Akt in the HCV life cycle. The result showed that Akt1 was a crucial host factor involved in the late stage of HCV life cycle. Akt1 depletion reduced viral particles released from Huh-7.5.1 cells to culture medium with consequent reduction of viral reinfection in cell culture system, which was restored by ectopic Akt1 expression. To further study the mechanism, we found that Akt1 enhanced lipogenic pathway through transcriptional activation of fatty acid synthase (FAS) by sterol regulatory element binding protein-1 (SREBP1) to maintain sufficient lipid droplet that is an essential organelle for assembly and release of HCV infectious virions.
Research Square Platform LLC
Title: Akt1 is required to maintain lipid droplets for release of HCV infectious virions
Description:
Abstract
Hepatitis C virus (HCV) relies on the interplay of viral and host factors to complete its life cycle.
It has evolved to benefit from Akt activation at some point in the life cycle through a variety of mechanisms.
Our preliminary result showed that Akt-specific inhibitor reduced cell culture-derived HCV (HCVcc) infectivity in a dose-dependent manner.
To dissect the mechanism, we adopted a two-part cell culture-derived HCV infection protocol with Akt1 small interfering RNAs (siRNAs) to determine the role of Akt in the HCV life cycle.
The result showed that Akt1 was a crucial host factor involved in the late stage of HCV life cycle.
Akt1 depletion reduced viral particles released from Huh-7.
5.
1 cells to culture medium with consequent reduction of viral reinfection in cell culture system, which was restored by ectopic Akt1 expression.
To further study the mechanism, we found that Akt1 enhanced lipogenic pathway through transcriptional activation of fatty acid synthase (FAS) by sterol regulatory element binding protein-1 (SREBP1) to maintain sufficient lipid droplet that is an essential organelle for assembly and release of HCV infectious virions.
Related Results
T cell responses from blood donors infected with different HCV genotypes against HCV 1a proteins
T cell responses from blood donors infected with different HCV genotypes against HCV 1a proteins
Hepatitis C virus (HCV) infection, which can cause chronic liver diseases, cirrhosis and hepatocellular carcinoma, is still a major public health problem worldwide. Upon comparing ...
Global Lipidome Profiling Revealed Multifaceted Role of Lipid Species in Hepatitis C Virus Replication, Assembly, and Host Antiviral Response
Global Lipidome Profiling Revealed Multifaceted Role of Lipid Species in Hepatitis C Virus Replication, Assembly, and Host Antiviral Response
Hepatitis C virus (HCV) is a major human pathogen that requires a better understanding of its interaction with host cells. There is a close association of HCV life cycle with host ...
AVALIAÇÃO DO TESTE SUPLEMENTAR GEENIUS HCV SUPPLEMENTAL ASSAY NA DISPARIDADE ENTRE RESULTADO DE TRIAGEM SOROLÓGICO-MOLECULAR PARA O VÍRUS DA HEPATITE C
AVALIAÇÃO DO TESTE SUPLEMENTAR GEENIUS HCV SUPPLEMENTAL ASSAY NA DISPARIDADE ENTRE RESULTADO DE TRIAGEM SOROLÓGICO-MOLECULAR PARA O VÍRUS DA HEPATITE C
INTRODUÇÃO: A detecção de HCV na triagem, em doadores de sangue da Fundação Hemopa, é realizada simultaneamente por um teste sorológico e um teste molecular. No caso de discordânci...
Hepatitis C virus genotypes, reactivity to recombinant immunoblot assay 2 antigens and liver disease
Hepatitis C virus genotypes, reactivity to recombinant immunoblot assay 2 antigens and liver disease
AbstractTo clarify the relationship between hepatitis C virus (HCV) genotypes and liver disease, we typed HCV genomes in the sera of 151 blood donors, 180 patients with type C chro...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
A11 NEXT STEPS IN MICRO-ELIMINATION: PEER POINT OF CARE HEPATITIS C TESTING IN VICTORIA, BRITISH COLUMBIA
A11 NEXT STEPS IN MICRO-ELIMINATION: PEER POINT OF CARE HEPATITIS C TESTING IN VICTORIA, BRITISH COLUMBIA
Abstract
Background
Canada is currently on target to reach the 2030 WHO goal of hepatitis C virus (HCV) elimination. Continued h...
Predictors of Missed Hepatitis C Intake Appointments and Failure to Establish Hepatitis C Care Among Patients Living With HIV
Predictors of Missed Hepatitis C Intake Appointments and Failure to Establish Hepatitis C Care Among Patients Living With HIV
Abstract
Background
We estimated and characterized the proportion of patients living with HIV (PLWH) who missed hepatitis C (HCV...
Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan
Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan
Abstract
Background
Most of Harm Reduction Service (HRS) users represent a crucial high-risk population for blood borne infectio...

